| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Lineage Cell Therapeutics Inc (TA: BTX)
BTX Technical Analysis
5
| As on 12th Oct 2025 BTX STOCK Price closed @ 588.10 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 306.81 & Strong Buy for SHORT-TERM with Stoploss of 395.62 we also expect STOCK to react on Following IMPORTANT LEVELS. |
BTXSTOCK Price
| Open | 588.80 | Change | Price | % |
| High | 588.80 | 1 Day | 15.30 | 2.67 |
| Low | 572.00 | 1 Week | 66.50 | 12.75 |
| Close | 588.10 | 1 Month | 176.10 | 42.74 |
| Volume | 14019 | 1 Year | 71.10 | 13.75 |
| 52 Week High 615.00 | 52 Week Low 144.50 | ||||
TA Israel Most Active Stocks
| TA125 | 2008.05 | 1.06% |
| XTLB | 4.80 | -14.29% |
| BLRX | 2.20 | -4.35% |
| ELAL | 1301.00 | -1.96% |
| BEZQ | 675.00 | 0.46% |
| ORL | 93.50 | -0.53% |
| MGDL | 1138.00 | -1.39% |
| TDGN-L | 171.50 | 17.55% |
| LUMI | 6420.00 | -0.47% |
| DSCT | 3280.00 | 0.99% |
TA Israel Top Gainers Stocks
TA Israel Top Losers Stocks
| BTX Daily Charts |
BTX Intraday Charts |
Whats New @ Bazaartrend |
BTX Free Analysis |
|
|
BTX Important Levels Intraday
| RESISTANCE | 620.47 |
| RESISTANCE | 610.09 |
| RESISTANCE | 603.67 |
| RESISTANCE | 597.26 |
| SUPPORT | 578.94 |
| SUPPORT | 572.53 |
| SUPPORT | 566.11 |
| SUPPORT | 555.73 |
BTX Forecast October 2025
| 4th UP Forecast | 918 |
| 3rd UP Forecast | 812.2 |
| 2nd UP Forecast | 746.8 |
| 1st UP Forecast | 681.4 |
| 1st DOWN Forecast | 494.8 |
| 2nd DOWN Forecast | 429.4 |
| 3rd DOWN Forecast | 364 |
| 4th DOWN Forecast | 258.2 |
BTX Weekly Forecast
| 4th UP Forecast | 756.13 |
| 3rd UP Forecast | 702.24 |
| 2nd UP Forecast | 668.93 |
| 1st UP Forecast | 635.62 |
| 1st DOWN Forecast | 540.58 |
| 2nd DOWN Forecast | 507.27 |
| 3rd DOWN Forecast | 473.96 |
| 4th DOWN Forecast | 420.07 |
BTX Forecast2025
| 4th UP Forecast | 1536.18 |
| 3rd UP Forecast | 1232.13 |
| 2nd UP Forecast | 1044.18 |
| 1st UP Forecast | 856.24 |
| 1st DOWN Forecast | 319.96 |
| 2nd DOWN Forecast | 132.02 |
| 3rd DOWN Forecast | -55.93 |
| 4th DOWN Forecast | -359.98 |
Lineage Cell Therapeutics Inc ( TA Israel Symbol : BTX )
Sector : Other And Other Stocks in Same Sector
Sector : Other And Other Stocks in Same Sector
BTX Business Profile
BioTime, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also develops Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy; ReGlyde, a HyStem product in preclinical development as a device for viscosupplementation, and as a platform for intraarticular drug delivery in osteoarthritis; and Premvia, a Hystem Hydrogel product, as well as develop bone grafting products for the orthopedic diseases and injuries. In addition, it markets GeneCards, a human gene database; MalaCards, a human disease database; and Hextend, a plasma volume expander used to treat or prevent hypovolemia, including albumin, generic 6% hetastarch solutions, and crystalloid solutions, as well as undertakes various research programs for vision restoration and Demyelination. The company has collaboration with Orbit Biomedical, Ltd. BioTime, Inc. was founded in 1990 and is headquartered in Alameda, California. Address:
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service